Rotterdam

• FUnctional selection of advanced breast cancer patients for Talazoparib treatment Using the REpair Capacity (RECAP) test: The FUTURE trial Ended
  2024-518036-36-03 6 2019-09-20 Breast cancer
• A Long-term Safety Extension Study of Mavacamten (MYK-461) in Adults with Hypertrophic Cardiomyopathy Who Have Completed the MAVERICKHCM (MY … Ended
  2022-502858-14-00 5 2019-09-05 Hypertrophic cardiomyopathy
• Phase 3 Study of Pembrolizumab plus Enzalutamide in mCRPC Ended
  2022-500785-10-00 5 2019-08-23 Metastatic Castration-Resistant Prostate Cancer
• NeoRay - Phase I/IIa trial of [177Lu]-NeoB in patients with advanced solid tumors and with [68Ga]-NeoB lesion uptake. Ended
  2023-507170-41-00 7 2019-07-29 Solid tumors known to overexpress GRPR and with [68Ga]-NeoB lesion upt
• OPTIMIZE Ended
  2024-516509-22-00 6 2019-07-22 kidney transplant
• A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of bb2121 Versus Standard Regimens in Subjects with … Ended
  2023-509848-10-00 5 2019-06-12 Multiple myeloma (MM) with at least 2 prior therapies including an imm
• Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke Ended
  2023-503673-38-00 5 2019-05-24 Adults at high risk of cardiovascular events without prior MI or strok
• Efficacy and safety of tisotumab vedotin (HuMax®-TF-ADC) monotherapy and in combination in recurrent or Stage IVB cervical cancer Ended
  2023-508832-68-00 9 2019-03-28 Recurrent or stage IVB cervical cancer
• A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabin … Ended
  2024-513513-12-00 5 2019-01-06 Cholangiocarcinoma
• A phase III trial investigating a gene therapy (AAV-hFIXco-Padua, AMT061), in adult patients with severe or moderately severe haemophilia B, … Ended
  2024-510738-42-00 5 2018-12-03 Haemophilia B
• Study to test the safety and how well patients with severe hemophilia A respond to treatment with BAY 2599023 (DTX 201), a drug therapy that … Ended
  2023-505827-29-00 7 2018-10-30 Hemophilia A
• Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3) (ZUMA-2) Ended
  2023-506641-35-00 4 2018-07-09 Relapsed/Refractory Mantle Cell Lymphoma
• Blinatumomab added to prephase and consolidation therapy in precursor B-acute lymphoblastic leukemia in adults. Ended
  2024-511050-44-00 4 2018-05-16 Precursor B-acute lymphoblastic leukemia
• A Study of Rilzabrutinib in Adult Patients With Immune Thrombocytopenia (ITP) Ended
  2023-509397-39-00 9 2018-03-20 Immune Thrombocytopenia
• A prospective, multicenter, phase-II trial of ibrutinib plus venetoclax in physically fit patients with creatinine clearance ≥ 30 ml/min who … Ended
  2023-510557-42-00 4 2017-07-10 chronic lymphocytic leukemia
• A phase I dose finding study of oral TNO155 in adult patients with advanced solid tumors Ended
  2023-508925-29-00 1 2017-06-29 Advanced solid tumors
• Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3 … Ended
  2022-501251-81-00 5 2017-06-08 Renal cell carcinoma
• A study of Ibrutinib in combination with Rituximab versus Placebo in combination with Rituximab in treatment of patients with Follicular Lym … Ended
  2023-507271-21-00 5 2017-04-11 Follicular Lymphoma
• GIVE trial (Gazyvaro In combination with VEnetoclax in Elderly CLL) Ended
  2024-511048-22-00 4 2016-10-27 Chronic lymphocytic leukemia
• autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction in Generalized mantle cell Lymphoma – a randomized Europea … Ended
  2024-511235-10-00 5 2016-07-25 Generalized mantle cell Lymphoma
• Pembrolizumab (MK-3475) and pembrolizumab in combination with other investigational agents in high risk NMIBC patients unresponsive to BCG Ended
  2022-502526-41-00 4 2016-03-15 Non-Muscle Invasive Bladder Cancer (NMIBC)
• A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 in Completely Resected Non-Small Cell Lung Can … Ended
  2024-517856-36-00 5 2015-03-09 Completely resected primary stage IB (≥ 4cm), II and IIIA non-small ce
• STRIDER: A phase II Study evaluaTing intRacranial effIcacy of JDQ443 in patiEnts with KRAS G12C+ NSCLC and bRain metastases Ended
  2023-505721-13-00 4 patients with KRAS G12C+ non small cell lung cancer and brain metastas
• DIONYSIUS Ended
  2024-511743-26-00 6 Symptomatic Ischemic Ulcer related to Diabetes

Showing 793–816 of 824 trials